Efficacy News and Research

RSS

Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

On Friday, March 18, the U.S. Food and Drug Administration approved Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs. Anthim is also approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate.

21 Mar 2016

Real-world studies support switching IBD patients from reference infliximab to biosimilar infliximab

Data presented today at the 11th Congress of European Crohn’s and Colitis Organisation adds to the growing body of real-world evidence that supports switching patients from reference infliximab to biosimilar infliximab.

21 Mar 2016

LEO Pharma announces scientific approval of Enstilar for treatment of people living with psoriasis in EU

LEO Pharma today announced that it received scientific approval of Enstilar (calcipotriol/betamethasone dipropionate 50 micrograms/g / 0,5 mg/g) for the treatment of psoriasis vulgaris in patients 18 years of age or older.

21 Mar 2016

Study assesses acceptability of alternative drug to prevent malaria among pregnant women in Kenya

Researchers at LSTM, working with colleagues at the Centres for Disease Control and Prevention USA, the Kenya Medical Research Institute, and from the London School of Hygiene and Tropical Medicine, have completed a study to assess the acceptability among pregnant women and health providers in Kenya of a new drug as an alternative to the standard drug used to prevent malaria in pregnancy.

21 Mar 2016

Neutralizing acidic tumor environment increases efficacy of immune-targeting cancer therapies

Cancer cells have the ability to grow in an acidic tumor environment that is detrimental to other cells, including immune cells. In a Cancer Research cover article published this week, Moffitt Cancer Center reported that neutralizing the acidic tumor environment increases the efficacy of several immune-targeting cancer therapies.

19 Mar 2016

Paracetamol does not meet minimum standard of clinical effectiveness in osteoarthritis patients

In a large-scale analysis of pain-relief medication for osteoarthritis, researchers found that paracetamol does not meet the minimum standard of clinical effectiveness in reducing pain or improving physical function in patients with knee and hip osteoarthritis.

18 Mar 2016

Findings could be final puzzle piece in developing effective dengue vaccine

In a small clinical trial led by the Johns Hopkins Bloomberg School of Public Health, researchers say that a promising single-dose dengue vaccine, developed by scientists at the National Institutes of Health, was 100 percent effective in preventing human volunteers from contracting the virus, the most prevalent mosquito-borne virus in the world.

18 Mar 2016

Study finds disparities in discontinuing diabetes drug rosiglitazone following FDA safety alert

Among older adults with diabetes, certain subgroups--including white patients and those with lower incomes--were slower to discontinue the diabetes drug rosiglitazone after a US Food and Drug Administration safety alert, reports a study in the April issue of Medical Care.

17 Mar 2016

Neural stem cells from T cell-derived iPSCs provide neurological disease model

Researchers in Japan report that neural stem cells derived from readily available T cell-derived iPSCs provide a neurological disease model when cultured in a novel protocol developed by them. The findings are important for the treatment of Parkinson’s disease and are published in Stem Cell Reports, March 2016.

16 Mar 2016

Study could lead to potential new therapeutic target with fewer side effects for hypertension

A team of Vermont investigators has been issued a patent for their discovery of a molecule that rescues damaged blood vessels, yet preserves healthy vessels and could serve as a springboard for a new pharmaceutical therapy with fewer side effects for hypertension - a major risk factor for cardiovascular and kidney disease that effects roughly one in three people in the U.S.

15 Mar 2016

New drug could transform treatment of metastatic triple negative breast cancer

A team of investigators from Houston Methodist Research Institute may have transformed the treatment of metastatic triple negative breast cancer by creating the first drug to successfully eliminate lung metastases in mice.

15 Mar 2016

Combining photoimmunotherapy and gene transduction effective against elusive gastric cancer cells

Researchers report photoimmunotherapy to be effective against elusive gastric cancer cells following transduction with the gene that expresses the extracellular domain protein of HER2. The results are published in the journal Small Molecule Therapeutics in February 2016.

15 Mar 2016

NIH-funded investigators develop therapeutic compound effective against malaria

An international team that includes NIH-funded researchers at Stanford University has developed a therapeutic compound that is effective in inhibiting Plasmodium falciparum, one of five species of parasite that infects people with malaria, and the strain which causes the highest number of malaria deaths.

13 Mar 2016

FDA approves Xalkori (crizotinib) to treat patients with ROS-1 positive NSCLC

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC.

13 Mar 2016

Delivering microRNAs in cancer treatment: an interview with Dr Conde and Prof Artzi

microRNAs (miRs) are small endogenous noncoding RNA molecules (20–23 nucleotides) derived from imperfectly paired hairpin RNA structures naturally encoded in the genome that act specifically as triggering molecules to control translational repression or mRNA degradation.

11 Mar 2016

New drug combination treatment makes breast cancer tumours disappear in just 11 days

Approximately a quarter of women with HER2 positive breast cancer, who were treated with a combination of the targeted drugs lapatinib and trastuzumab before surgery and chemotherapy, saw their tumours shrink significantly or even disappear, according to results from a clinical trial.

11 Mar 2016

Breast cancer can be more aggressive in obese people

An international team of researchers, with the participation of the University of Granada, has revealed new data on why breast cancer has a higher incidence and is more aggressive in obese people. The reason is that peritumoral fat (the fat around the tumor) facilitates the expansion and invasion of cancer stem cells (CSCs), which are responsible of the onset and growth of the tumor.

11 Mar 2016

Phase 3 study: Sarilumab monotherapy meets primary endpoint in active rheumatoid arthritis patients

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Phase 3 monotherapy study met its primary endpoint demonstrating that sarilumab was superior to adalimumab (marketed by AbbVie as HUMIRA) in improving signs and symptoms in patients with active rheumatoid arthritis (RA) at Week 24.

11 Mar 2016

Excess comorbidity flagged in MS patients

Patients with multiple sclerosis have more comorbidities than would be expected for their age, even at the time of diagnosis, say researchers.

10 Mar 2016

BioLineRx announces year end 2015 financial results, provides operational update

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the year ended December 31, 2015.

10 Mar 2016

Efficacy News and Research

Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

Real-world studies support switching IBD patients from reference infliximab to biosimilar infliximab

LEO Pharma announces scientific approval of Enstilar for treatment of people living with psoriasis in EU

Study assesses acceptability of alternative drug to prevent malaria among pregnant women in Kenya

Neutralizing acidic tumor environment increases efficacy of immune-targeting cancer therapies

Paracetamol does not meet minimum standard of clinical effectiveness in osteoarthritis patients

Findings could be final puzzle piece in developing effective dengue vaccine

Study finds disparities in discontinuing diabetes drug rosiglitazone following FDA safety alert

Neural stem cells from T cell-derived iPSCs provide neurological disease model

Study could lead to potential new therapeutic target with fewer side effects for hypertension

New drug could transform treatment of metastatic triple negative breast cancer

Combining photoimmunotherapy and gene transduction effective against elusive gastric cancer cells

NIH-funded investigators develop therapeutic compound effective against malaria

FDA approves Xalkori (crizotinib) to treat patients with ROS-1 positive NSCLC

Delivering microRNAs in cancer treatment: an interview with Dr Conde and Prof Artzi

New drug combination treatment makes breast cancer tumours disappear in just 11 days

Breast cancer can be more aggressive in obese people

Phase 3 study: Sarilumab monotherapy meets primary endpoint in active rheumatoid arthritis patients

Excess comorbidity flagged in MS patients

BioLineRx announces year end 2015 financial results, provides operational update

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News